Rada-Pharma

2021: Plans of start of an additional production line

The Rada-Pharma company at the end of 2020 received the status of the resident of the Technopolice Moscow special economic zone and is going to invest till 2022 in start of a production line more than 40 million rubles. The enterprise specializes in production of medicines and medical products on the basis of a chlorophyll for photodynamic therapy which is applied at treatment of oncological, gynecologic and dermatological diseases, Tekhnolis reported about it on January 21, 2021 according to the Head of Department of investment and industrial policy Alexander Prokhorov.

The method of photodynamic therapy is based on selective accumulation of active agent of medicine in malignant new growths which collapse in interaction with a laser radiation of a certain wavelength, without injuring at the same time healthy cells.

The Rada-Pharma enterprise for January, 2021 produces about 12.5 thousand medicines and medical products annually, and by the end of 2026 input of the additional line will allow to increase production by a third, to 17 thousand pieces. For January 21, 2021 a share the Rada-Pharma company in the domestic market of sales of medicines for photodynamic therapy makes about 66 percent, – the head of department told.

The status of the resident of the special economic zone "Technopolice "Moscow" will give to the enterprise the chance to save annually significantly on taxes and other obligatory payments: reduced income tax rate, duty-free import and a zero rate on property and transport will be available to the company. The company is going to allocate the funds saved in the budget for logistics improvement, creation of new developments and the training programs.

Thanks to investments the resident is also going to increase the share in the domestic market, the CEO of the Technopolice Moscow SEZ Gennady Dyogtev told.

Rada-Pharma is localized in the territory of the special economic zone since 2014. Products of the enterprise are delivered in the state hospitals, private clinics and drugstores more than 50 regions of the country. Obtaining resident status and all tax preferences, input of the additional line of the equipment and preserving of the prices is one quarter lower, than at competitors, will allow the company to increase the share in the Russian market of medicines for photodynamic therapy to 70 percent, – Gennady Dyogtev specified.